Int J Med Sci 2017; 14(11):1094-1100. doi:10.7150/ijms.20414 This issue

Research Paper

Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression

Wei-En Yang1, 2, Ming-Ju Hsieh2, 3, 4, Chiao-Wen Lin5, 6, Chun-Ying Kuo7, Shun-Fa Yang1, 2, Chun-Yi Chuang8, 9 Corresponding address, Mu-Kuan Chen2, 7 Corresponding address

1. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan;
2. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan;
3. Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan;
4. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan;
5. Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan;
6. Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan;
7. Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan;
8. School of Medicine, Chung Shan Medical University, Taichung, Taiwan;
9. Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license ( See for full terms and conditions.
Yang WE, Hsieh MJ, Lin CW, Kuo CY, Yang SF, Chuang CY, Chen MK. Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression. Int J Med Sci 2017; 14(11):1094-1100. doi:10.7150/ijms.20414. Available from

File import instruction


In Taiwan, oral cancer is the fourth most common cancer and the most common malignancy with a poor prognosis. Endothelial cell-specific molecule-1 (ESM-1) is secreted by vascular endothelial cells in the liver, lungs, kidneys, and gastrointestinal tract. ESM-1 expression is associated with tumor prognosis, metastasis, and angiogenesis in many cancers. However, few studies have examined the association of plasma ESM-1 levels with oral squamous cell carcinoma (OSCC) progression. We measured the plasma ESM-1 levels of 438 male OSCC patients through a commercial enzyme-linked immunosorbent assay. The Cancer Genome Atlas (TCGA) dataset was also used to analyze the ESM-1 levels in 328 OSCC patients and 33 normal tissues. Our results revealed that the plasma levels of ESM-1 in OSCC patients were significantly associated with the tumor (T) status but not with the lymph node status, metastasis, and cell differentiation. TCGA bioinformatics database analysis revealed that ESM-1 expression was significantly higher in OSCC patients than in normal individuals (p < 0.05). In addition, the examination revealed similar results for the ESM-1 expression levels and pathological stage in OSCC. In conclusion, plasma ESM-1 is a novel biomarker for predicting the T status in OSCC patients.

Keywords: ESM-1, oral squamous cell carcinoma, biomarker.


Oral cancer, which involves malignant tumors that affect any region of the oral cavity, lip, salivary glands, and pharyngeal regions, is a major problem concerning human health worldwide. Oral squamous cell carcinoma (OSCC) is the most frequently (approximately 90%) occurring malignant oral cancer, and the incidence and prevalence have increased in recent years, especially in Asian countries [1-3]. The major risk factors for oral cancer are smoking and alcohol, which have been noted in 90% of oral cancer cases [4]. Surgery is the preferred treatment approach for OSCC. The recurrence of OSCC is due to local metastasis and invasion, leading to a poor prognosis [5, 6]. Therefore, more accurate and acceptable biomarkers must be developed for early cancer detection and to predict OSCC progression.

Endothelial cell-specific molecule-1 (ESM-1) or endocan is a 50-kDa secretory proteoglycan composed of a 165-amino acid mature protein core (20 kDa) and approximately 30 kDa of a unique dermatan sulfate chain linked to serine residues [7-9]. It is predominantly secreted by vascular endothelial cells from the liver, lungs, gastrointestinal tract, and kidneys [10, 11]. ESM-1 production is highly regulated by the environment. Angiogenic factors and inflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor-α (TNF-α), induce ESM-1 expression and are strongly downregulated by IL-4 and interferon-γ [7, 8, 10] . ESM-1 is expressed not only in normal tissues but also in various types of tumors, with differential expression levels in glioblastoma [12], non-small cell lung cancer [13], gastric cancer [14], colorectal cancer [14], renal cell cancer [15, 16], bladder cancer [17], ovarian cancer [18], hepatocellular carcinoma [19], and acute myeloid leukemia [20]. ESM-1 plays an influential role in angiogenesis and tumor growth. In tumor tissues, angiogenesis is crucial for progression and is an indicator of poor prognosis. ESM-1 levels are associated with increased proangiogenesis growth factors, such as fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), and hepatocyte growth factor/scatter factor, and are regulated by VEGF [8, 21]. ESM-1 is also overexpressed at the mRNA and/or protein levels in cancer tissues, and it has been related to tumor progression and poorer survival [22, 23]. Moreover, a meta-analysis study which including 15 eligible studies of 1,464 patients also mentioned that high ESM-1 expression predicts poor overall survival in gastrointestinal and hepatocellular carcinoma [24].

Previously, ESM-1 has been observed not only in the serum of septic patients [25] but also as a potential serum biomarker in gastric cancer [26], bladder cancer [27], colorectal cancer [28] and hepatocellular carcinoma [29] patients. Furthermore, higher levels of serum ESM-1 are correlated with a poor prognosis [30]. However, whether serum ESM-1 levels are elevated in OSCC patients remains unclear, and the association between the serum levels of ESM-1 and prognosis of OSCC patients has not been elucidated. The present study examined whether serum ESM-1 can be used as a biomarker for the early diagnosis of OSCC.

Materials and Methods

Patient Specimens

In total, 438 OSCC male patients (mean age, 55.23 years) from 2008 to 2012 were recruited from Chung Shan Medical University Hospital in Taichung and Changhua Christian Hospital in Changhua, Taiwan. Data of the tumor stage, tumor, node, and metastasis (TNM) status and cell differentiation were obtained from the medical records of the OSCC patients. The OSCC patients were diagnosed according to the TNM classification, which is described in the American Joint Committee on Cancer (AJCC) Staging Manual, seventh edition.

Whole peripheral blood samples were collected from OSCC patients and placed in EDTA tubes. After the centrifugation of the blood samples at 3000 rpm for 10 min, the supernatants were placed at -80°C. This study was approved by the Institutional Review Board of Chung Shan Medical University Hospital (CSMUH No: CS13214-1), and informed written consent for participation was obtained from all participants. Table 1 shows the clinical characteristics of the patients.

 Table 1 

Demographic characteristics and clinical features of OSCC patients.

VariablesOSCC (n = 438)
Age (years)55.23 ± 10.82
Smoking status
No46 (10.5%)
Yes392 (89.5%)
Drinking status
No205 (46.8%)
Yes233 (53.2%)
Betel nuts chewing
No86 (19.6%)
Yes352 (80.4%)
Cancer location
Buccal mucosa157 (35.8% )
Tongue130 (29.7 %)
Gingiva68 (15.5 %)
Others83 (18.9 %)
I118 (27.0%)
II79 (18.0%)
III43 (9.8%)
IV198 (45.2%)
Tumor T status
T1141 (32.2%)
T2120 (27.4%)
T337 (8.4%)
T4140 (32.0%)
Lymph node status
N0287 (65.5%)
N148 (11.0%)
N299 (22.6%)
N34 (0.9%)
M0436 (99.5%)
M12 (0.5%)
Cell differentiation
Well differentiated59 (13.5%)
Moderately or poorly differentiated379 (86.5%)

Quantitative Analysis of Plasma ESM-1 Levels

The ESM-1 levels in the plasma samples of OSCC were analyzed using an ESM-1 Human ELISA Kit (LIK-1205, Lunginnov, Lille, France). The prepared standards and samples were added to an ELISA plate, according to the manufacturer instructions. After reading the absorbance of each well at 450 nm in a microtest plate spectrophotometer (STNERGY/H4, BioTek Instruments, Inc., Winoosi, VT, USA), the ESM-1 levels were quantified using a calibration curve, with the provided human ESM-1 as a standard.

Expression Analysis of The Cancer Genome Atlas OSCC data

The Cancer Genome Atlas (TCGA; URL: was used to obtain the ESM-1 normalized expression data and associated clinical data, which corresponds to the head and neck squamous cell carcinoma dataset (n = 528). After filtering the samples, we included only one of six oral cancer anatomic subtypes (alveolar ridge, base of tongue, buccal mucosa, floor of mouth, oral cavity, and oral tongue; filtered oral cancer dataset size: n = 328). Box plots for ESM-1 expression values were generated with respect to the tumor grade/stage and TNM status.

Statistical Analysis

The standard deviation of the mean was used to express the values. The statistical significance of the means for ESM-1 levels was determined using the Mann-Whitney Rank sum test between groups. In addition, alcohol consumption status, smoking status, and betel nuts chewing status were analyzed using the Chi-squared test. Student t-test was used to calculate the significances of the differences. Analyses were performed using SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA). Statistical significance was set at p < 0.05.


Demographic Data

In this study, only male OSCC patients (n = 438) were included. The demographic data presents the tumor stage, TNM status, and tumor differentiation status of these patients (Table 1). Among these patients, 89.5% smoked, 53.2% consumed alcohol, and 80.4% chewed betel nut. The tumors were located in the buccal mucosa (n = 157), tongue (n = 130), gingiva (n = 68), and other parts (n = 83).

Correlation of Plasma ESM-1 Levels and Clinicopathological Characteristics of OSCC Patients

The mean plasma ESM-1 levels were significantly higher in stage II patients (2.58 ± 1.39 ng/mL) than in stage I (2.1 ± 1.32 ng/mL) patients (p = 0.016; Figure 1A). In addition, the mean plasma ESM-1 levels were significantly higher in patients with T2 status (2.47 ± 1.31 ng/mL) than in patients with T1 status (2.09 ± 1.32 ng/mL) (p = 0.021; Figure 1B). No significant differences were noted between the N statuses (Figure 1C). The correlation of plasma ESM-1 levels with the clinicopathological characteristics is presented in Table 2. High plasma ESM-1 levels were significantly associated with the T status. Compared with patients with low plasma ESM-1 levels, a higher proportion of patients with high plasma ESM-1 levels had T1-T3 status (77.3% vs. 62.2%; p = 0.001).

 Figure 1 

ELISA-determined plasma ESM-1 level of OSCC patients. ESM-1 levels were compared according to stage (A), T status (B) and N status (C).

Int J Med Sci Image

(View in new window)

Correlation of ESM-1 Levels and Clinicopathological Characteristics of OSCC Patients From TCGA

TCGA OSCC database was used to verify the findings of our study. The ESM-1 mRNA levels, pathological stage, pathological T and N status of OSCC, and normal tissues were assessed. The ESM-1 expression levels in different cancer types are shown in Figure 2A. Higher ESM-1 levels were detected in OSCC tissues than in normal tissues (p = 0.03; Figure 2B). Among the OSCC patients, the relative levels of ESM-1 mRNA were significantly higher in stage III patients than in stage I patients (p = 0.0221; Figure 2C). The relative levels of ESM-1 mRNA were significantly higher in patients with T3 status than in patients with T1 status (p = 0.0138; Figure 2D). However, the relative levels of ESM-1 mRNA were not significantly associated with the N status (Figure 2E).

 Table 2 

Correlation between plasma levels of ESM-1 and clinicopathological parameters in 438 OSCC patients.

ESM-1 levelsp value
VariablesLow levels (n=275)High levels (n=163)
Age (years)
<55143 (52.0%)66 (40.5%)0.020*
≥55132 (48.0%)97 (59.5%)
Smoking status
No28 (10.2%)18 (11.0%)0.776
Yes247 (89.8%)145 (89.0%)
Drinking status
No116 (42.2%)89 (54.6%)0.012*
Yes159 (57.8%)74 (45.4%)
Betel nuts chewing
No53 (19.3%)33 (20.2%)0.804
Yes222 (80.7%)130 (79.8%)
Cancer location
Buccal mucosa109 (39.6% )48 (27.4% )0.196
Tongue76 (27.6 %)54 (33.2 %)
Gingiva40 (14.5 %)28 (17.2 %)
Others50 (18.3 %)33 (20.2 %)
I+II127 (46.2% )71 (43.6% )0.594
III+IV148 (53.8 %)92 (56.4 %)
Tumor T status
T1104 (37.8% )37 (22.7% )0.001*
T2+T3+T4171 (62.2 %)126 (77.3 %)
Lymph node status
N0184 (66.9%)103 (63.2%)0.429
N1+N2+N391 (33.1%)60 (36.8%)
M0275 (100.0%)161 (98.8%)0.066
M10 (0%)2 (1.2%)
Cell differentiation
Well differentiated37 (13.5%)22 (13.5%)0.990
Moderately or poorly differentiated238 (86.5%)141 (86.5%)



ESM-1 is a soluble proteoglycan and a freely circulating molecule in the blood; hence, it has high potential as a biomarker. This is the first study to investigate the potential roles of ESM-1 in the peripheral blood of OSCC patients and the association between the plasma ESM-1 levels and clinicopathological characteristics. In this study, the plasma ESM-1 levels of OSCC patients were significantly associated with the tumor stage and T status. Similar results were also obtained in TCGA bioinformatics database analysis.

Tumor progression is a complex process, and the microenvironment not only plays a crucial role in cancer progression but also has profound effects on metastasis and angiogenesis [31-34]. ESM-1 expression is regulated by various cytokines and cell factors, such as IL-1 and ΤΝF-α, which may promptly induce increased serum ESM-1 expression to regulate tumor-associated inflammation [25]. Increased ESM-1 expression by endothelial cells is associated with certain angiogenic factors, such as FGF-2 and VEGF-A [35]. In human renal cancer, VEGF-A regulates ESM-1 expression through the PI3K/Akt signaling pathway and the protein kinase C activator [15]; VEGF-C and nuclear factor-κB (NF-κB) upregulate ESM-1. In ESM-1 knockout mice, vascular outgrowth was delayed, filopodia extension was reduced, phosphorylated Erk1/2 (extracellular signal-regulated kinases 1/2) expression in sprouting vessels was decreased, and VEGF-A-dependent processes were effected [35]. Thus, ESM-1 plays a role in angiogenesis and inflammation. Numerous studies have demonstrated that ESM-1 can be used as a potential biomarker for detection in gastric cancer [36], bladder cancer [37], colorectal cancer [28], hepatocellular carcinoma [38], pituitary adenoma [39], ovarian cancer [40], breast cancer [41], and acute leukemia [20], but ESM-1 has not been investigated in OSCC.

In various cancers, higher than normal ESM-1 expression levels have been detected. In addition, tumor size has been positively correlated with circulating ESM-1 expression levels. In colorectal cancer, knockdown ESM-1 expression may affect cell cycle arrest, decrease cyclin D1, and regulate metastatic process through the decline of NF-κB, phosphor-Akt, and GSK3α/3β expression [42]. In SK-Hep1 cells, ESM-1 siRNA expression indicates that ESM-1 may increase the survival rate through the NF-κB/IκB pathway [43]. Moreover, ESM-1 expression was associated with higher serum alpha fetoprotein levels and larger tumor in early hepatocellular carcinoma [44]. The metastatic process is also inhibited through the regulation of matrix metalloproteinase (MMP)- and epithelial-to-mesenchymal transition-related genes in cells with lower ESM-1 expression [42]. In murine OSCC, ESM-1 mediates nerve growth factor receptor (NGFR)-induced metastasis and invasion. Cells with ESM-1 overexpression may exhibit enhanced cell invasion and migration in vitro. In severe combined immunodeficient mice with NGFR-induced tumors, ESM-1 knockdown cells may reduce tumor formation and metastasis [45]. However, our study did not examine the regulation of plasma ESM-1 levels. In the future, we will examine the possible mechanisms of ESM-1 expression in OSCC.

 Figure 2 

ESM-1 mRNA level of OSCC patients from TCGA database. (A) The different of ESM-1 mRNA level from The Broad Institute TCGA GDAC Firehose in different type of cancer. (B) ESM-1 levels were compared according to normal people and OSCC patients. (C) ESM-1 levels were compared according to stage. (D) ESM-1 levels were compared according to tumor T status. (E) ESM-1 levels were compared according to N status. SARC: sarcoma. LIHC: liver hepatocellular carcinoma. KIRC: kidney renal clear cell carcinoma. HNSC: head and neck squamous cell carcinoma. GBM: Glioblastoma multiforme. COADREAD: colorectal adenocarcinoma. COAD: colon adenocarcinoma. CESC: cervical and endocervical cancers. BRCA: breast invasive carcinoma. BLCA: bladder urothelial carcinoma.

Int J Med Sci Image

(View in new window)

Most studies have indicated that ESM-1 is overexpressed in various cancer types and is associated with tumor progression and poor prognosis. However, contrary results have been reported in prostate cancer cells. Knockdown ESM-1 enhanced cell viability, cell migration, and cell invasion in vitro and increased the tumorigenesis and metastasis of prostate xenograft tumors in vivo through the regulation of TIMP-1/MMP-9 expression. ESM-1 plays a role in tumor suppression in prostate cancer cells [46].

In conclusion, our study revealed that plasma ESM-1 levels are useful for the detection of disease progression in OSCC patients. This is the first study to analyze plasma ESM-1 levels in patients with OSCC. We demonstrated that plasma ESM-1 levels were significantly associated with the T status in OSCC patients. As a secreted protein, ESM-1 may act as a potential marker of OSCC during tumor progression and can accordingly be used for disease diagnosis; furthermore, it plays a critical role in carcinogenesis.


This study was financially supported by grants from Ministry of Science and Technology, Taiwan (MOST-104-2314-B-371-008-MY2), Chung Shan Medical University and Changhua Christian Hospital (CSMU-CCH-105-04). This study was supported by the grant from Chang Shan Medical University Hospital (CSH-2017-C-016).

Competing Interests

The authors have declared that no competing interest exists.


1. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14-32

2. Bagan JV, Scully C. Recent advances in Oral Oncology 2007: epidemiology, aetiopathogenesis, diagnosis and prognostication. Oral Oncol. 2008;44:103-108

3. Su SC, Lin CW, Liu YF, Fan WL, Chen MK, Yu CP, Yang WE, Su CW, Chuang CY, Li WH, Chung WH, Yang SF. Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Theranostics. 2017;7:1088-1099

4. Dissanayaka WL, Pitiyage G, Kumarasiri PV, Liyanage RL, Dias KD, Tilakaratne WM. Clinical and histopathologic parameters in survival of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:518-525

5. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884-11894

6. Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: Mechanisms of inhibition by melatonin. J Pineal Res. 2017;62:e12370

7. Lassalle P, Molet S, Janin A, Van der Heyden J, Tavernier J, Fiers W, Devos R, Tonnel A-B. ESM-1 Is a Novel Human Endothelial Cell-specific Molecule Expressed in Lung and Regulated by Cytokines. J Biol Chem. 1996;271:20458-20464

8. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25-37

9. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P, Jude B, Janin A, Fernig DG, Tonnel A-B, Lassalle P. Endocan is a novel chondroitin sulfate / dermatan sulfate proteoglycan which promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276:48341-48349

10. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, Janin A, Tonnel AB, Lassalle P. Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal Antibodies. J Vasc Res. 2000;37:417-425

11. Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172-178

12. Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009;68:633-641

13. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res. 2006;12:4575-4582

14. Liu N, Zhang LH, Du H, Hu Y, Zhang GG, Wang XH, Li JY, Ji JF. Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol. 2010;17:2628-2639

15. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res. 2007;313:1285-1294

16. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, Delehedde M, Copin M-C, Lassalle P. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56:180-187

17. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stöhr R, Hartmann A, Provenzano M, Otto VI, Detmar M. Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A-Induced Angiogenesis. Cancer Res. 2013;73:1097-1106

18. El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. 2013;288:1371-1376

19. Huang G-W, Tao Y-M, Ding X. Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma. Dig Dis Sci. 2009;54:389-394

20. Xu Z, Zhang S, Zhou Q, Wang Y, Xia R. Endocan, a potential prognostic and diagnostic biomarker of acute leukemia. Mol Cell Biochem. 2014;395:117-123

21. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB, Lassalle P. Overexpression of endocan induces tumor formation. Cancer Res. 2003;63:6084-6089

22. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte J-J, Copin M-C, Tonnel A-B, Lassalle P, Group TTO. Endocan Expression and Relationship with Survival in Human Non-Small Cell Lung Cancer. Clin Cancer Res. 2006;12:4575-4582

23. El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. 2013;288:1371-1376

24. Huang X, Chen C, Wang X, Zhang JY, Ren BH, Ma DW, Xia L, Xu XY, Xu L. Prognostic value of endocan expression in cancers: evidence from meta-analysis. Onco Targets Ther. 2016;9:6297-6304

25. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P. Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532-537

26. Lv Z, Fan Y, Chen H, Zhao D. Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer. Tumor Biol. 2014;35:10497-10502

27. Laloglu E, Aksoy H, Aksoy Y, Ozkaya F, Akcay F. The determination of serum and urinary endocan concentrations in patients with bladder cancer. Ann Clin Biochem. 2016

28. Ji NY, Kim YH, Jang YJ, Kang YH, Lee CI, Kim JW, Yeom YI, Chun HK, Choi YH, Kim JH, Kim JW, Lee HG, Song EY. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci. 2010;101:2248-2253

29. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum Endocan as a Novel Prognostic Biomarker in Patients with Hepatocellular Carcinoma. J Cancer. 2014;5:221-230

30. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009;54:389-394

31. Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20:551-566

32. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci. 2017;18:E843

33. Chien MH, Lin CW, Cheng CW, Wen YC, Yang SF. Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opin Ther Targets. 2013;17:203-216

34. Ho HY, Lin CW, Chien MH, Reiter RJ, Su SC, Hsieh YH, Yang SF. Melatonin suppresses TPA-induced metastasis by downregulating matrix metalloproteinase-9 expression through JNK/SP-1 signaling in nasopharyngeal carcinoma. J Pineal Res. 2016;61:479-492

35. Yang J, Yang Q, Yu S, Zhang X. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 2015;3:279-283

36. Chang Y, Niu W, Lian PL, Wang XQ, Meng ZX, Liu Y, Zhao R. Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer. World J Gastroenterol. 2016;22:5422-5429

37. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M, Otto VI, Detmar M. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 2013;73:1097-1106

38. Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev. 2013;22:1343-1352

39. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757-764

40. Laloglu E, Kumtepe Y, Aksoy H, Topdagi Yilmaz EP. Serum endocan levels in endometrial and ovarian cancers. J Clin Lab Anal. 2016 doi: 10.1002/jcla.22079

41. Sagara A, Igarashi K, Otsuka M, Kodama A, Yamashita M, Sugiura R, Karasawa T, Arakawa K, Narita M, Kuzumaki N, Narita M, Kato Y. Endocan as a prognostic biomarker of triple-negative breast cancer. Breast Cancer Res Treat. 2017;161:269-278

42. Kang YH, Ji NY, Han SR, Lee CI, Kim JW, Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW, Ahn DK, Lee HG, Song EY. ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal. 2012;24:1940-1949

43. Kang YH, Ji NY, Lee CI, Lee HG, Kim JW, Yeom YI, Kim DG, Yoon SK, Kim JW, Park PJ, Song EY. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids. 2011;40:1003-1013

44. Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N'Kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrie N. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol. 2013;59:1264-1270

45. Chen C, Shin JH, Eggold JT, Chung MK, Zhang LH, Lee J, Sunwoo JB. ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma. Oncotarget. 2016;7:70738-70749

46. Chen CM, Lin CL, Chiou HL, Hsieh SC, Lin CL, Cheng CW, Hung CH, Tsai JP, Hsieh YH. Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget. 2017;8:13886-13897

Author contact

Corresponding address Corresponding authors: Mu-Kuan Chen, M.D., PhD., Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan; E-mail: Or Chun-Yi Chuang, M.D., PhD., School of Medicine, Chung Shan Medical University, Taichung, Taiwan. Telephone: +886-4-24739595 ext. 34255; E-mail: cyi4602com

Received 2017-4-5
Accepted 2017-7-5
Published 2017-9-4